This narrative review examines the use of biologic therapy in pediatric patients. The authors discuss a specific safety concern where these treatments might cause paradoxical inflammatory reactions. This means the immune system could react against the treatment itself in unexpected ways.
The review suggests that these reactions are not just coincidental bad luck. Instead, they may result from selective immune pressure, which is a consistent biological consequence of the therapy. This finding helps explain why some patients experience inflammation despite the treatment's intended goal.
However, the authors note that a unified mechanistic framework and practical clinical approach are still lacking, particularly for children. Because of this gap, the main takeaway is to support early recognition of these reactions and to adapt management based on their severity. More research is needed to fully understand these events before they can be managed with confidence.
